Skip to main content

Table 4 Patient response summary and target lesions

From: Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

 

Response

Partial response, n

Stable disease, n

Progressive disease, n

Overall patients (n = 20)

7

11

2

Total lesion (n = 55)

15

33

7

Pancreas (n = 7)

0

5

2

Liver (n = 37)

12

22

3

Lymph node (n = 10)

3

5

2

Peritoneal seeding (n = 1)

0

1

0